RedHill Acquires Commercialization Rights to Ferring's Rebyota and Clenpiq
RDHL sits 58% above its 52-week low of $0.57 on elevated volume (56× avg).
Summary
RedHill Biopharma has acquired commercialization rights to Ferring's Rebyota and Clenpiq, two FDA-approved gastrointestinal products. This is a transformative deal for the micro-cap company, which has been struggling with going concern warnings and dilutive financings. The acquisition adds two revenue-generating assets to RedHill's portfolio, potentially improving its financial outlook. The deal follows the recent sale of its Talicia stake to Apotex for $18M upfront, suggesting a strategic pivot toward commercial-stage products. No financial terms were disclosed, but the addition of marketed products could materially change RedHill's revenue trajectory.
At the time of this announcement, RDHL was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.57 to $2.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.